Could a superfruit boost immunotherapy for kidney cancer?
NCT ID NCT06049576
First seen Jan 07, 2026 · Last updated Apr 30, 2026 · Updated 14 times
Summary
This early-phase trial tests whether adding camu camu, a prebiotic fruit, to standard immunotherapy (nivolumab and ipilimumab) is safe and effective for people with advanced kidney cancer that has spread. About 31 participants will receive the combination to see if it improves gut bacteria linked to better immune response. The goal is to find the best dose and check if the treatment helps control the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV RENAL CELL CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.